Alexion Pharma

Wilson Therapeutics is a biopharmaceutical company based in Stockholm, Sweden, that develops novel therapies for rare diseases. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX. As of 2016, tetrathiomolybdate had been tested in over 500 patients for up to seven years, primarily in oncology and Wilson's disease, as well as some other clinical pathologies.

Wilson Therapeutics

Synageva was a publicly listed biopharmaceutical company headquartered in Lexington, Massachusetts dedicated to discovering, developing and delivering medicines for patients with rare diseases and high unmet medical needs. The company had manufacturing and laboratory locations in Lexington and Holden, Massachusetts, Bogart and Athens Georgia, as well as offices in a variety of locations around the world.

Synageva

Alexion Pharmaceuticals is a biopharmaceutical company, which is engaged in the discovery, development, and commercialization of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states, including hematologic, kidney and neurologic diseases, transplant rejection, cancer, and autoimmune disorders. Its marketed product Soliris (eculizumab) is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH).  In April 2009 and August 2009, the United States food and drug administration (FDA) and the European Commission (E.C.), respectively, granted Soliris orphan drug designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). In December 2009, its Rhode Island manufacturing facility received regulatory approval from the E.C. Or the production of Soliris.

BOSTON--(BUSINESS WIRE)--Alexion Reports Fourth Quarter and Full Year 2020 Results

Alexion Reports Fourth Quarter and Full Year 2020 Results

Alexion (ALXN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Alexion (ALXN)

Alexion (ALXN) is set to provide updates on revenues and earnings when it releases fourth-quarter 2020 results on Feb 4.

Alexion (ALXN) to Report Q4 Earnings: What's in the Cards?

Amgen

Biogen

Gilead Sciences

Merck

Pfizer

AbbVie

Bristol-Myers

Regeneron Pharmaceuticals

Earnings season is in full swing, and we have put together a preview of some of the world's largest players in the health care sector reporting this coming week.

Amgen, Biogen, Gilead, Merck, Pfizer, and More Health Care Earnings Coming This Week

CVS Health

AT&T

Vertex Pharmaceuticals

Verizon

Walgreens

You can still find deeply discounted stocks if you do a little digging.

3 Industries That Are Screaming Bargains in an Otherwise Pricey Market

Alexion (ALXN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alexion Pharmaceuticals (ALXN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

BioMarin Pharmaceutical

ALXN vs. BMRN: Which Stock Is the Better Value Option?

ALXN vs. BMRN: Which Stock Should Value Investors Buy Now?

BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2020 before the US financial markets open on February 4, 2021. Given the recently announced agreement to be acquired by AstraZeneca, Alexion will not be hosting a conference call. Earnings materials will be made available publicly on the Investor Relations page of our website at http://ir.alexion.com. Que

Alexion to Report Fourth Quarter and Full Year 2020 Results on Thursday, February 4, 2021

Alexion (ALXN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Alexion (ALXN) Beat Estimates Again in Its Next Earnings Report?

NEW YORK, Jan. 14, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) concerning potential violations of the federal securities laws and/or breaches of fiduciary...

INVESTIGATION ALERT: Halper Sadeh LLP Investigates ALXN, CHNG, RP, RNET, MDCA, NK; Shareholders Are Encouraged to Contact the Firm

Alexion (ALXN) decides to stop further enrollment in the late-stage study of Ultomiris in adults with severe COVID-19 requiring mechanical ventilation due to lack of efficacy.

Alexion (ALXN) to Pause Enrollment in COVID-19 Study on Ultomiris

Adient

Affiliated Managers

General Motors

P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high growth prospects.

4 Promising Price-to-Book Value Stocks to Buy Now

Alexion Pharmaceuticals Inc. ALXN said late Wednesday it stopped enrolling patients in a clinical study testing a treatment for severe COVID-19 patients based on the recommendation of a data monitoring board. The independent data monitoring committee for the Phase 3 study of the drug Ultomiris said further enrollment of patients should be paused pending more data analysis as the treatment was not looking to be effective in treating COVID-19 patients on ventilators when compared with standard care, the company said.

Alexion Pharma pauses further enrollment in COVID-19 drug study

BOSTON--(BUSINESS WIRE)--Alexion Highlights Commercial, Clinical and Financial Progress at the 39th Annual J.P. Morgan Healthcare Conference

Alexion Highlights Commercial, Clinical and Financial Progress at the 39th Annual J.P. Morgan Healthcare Conference

ALXN or BMRN: Which Is the Better Value Stock Right Now?

BOSTON--(BUSINESS WIRE)--Alexion to Present at the 39th Annual J.P. Morgan Healthcare Conference

Alexion to Present at the 39th Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 5, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) concerning potential violations of the federal securities laws and/or breaches of fiduciary...

ALERT: Halper Sadeh LLP Investigates ALXN, SPWH, CBMG, STND, EIDX; Shareholders Are Encouraged to Contact the Firm

NEW YORK, Dec. 24, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) concerning potential violations of the federal securities laws and/or breaches of fiduciary...

ALERT: Halper Sadeh LLP Continues to Investigate the Following Mergers - ALXN, TCF, CATM, TCP

AstraZeneca

Is AstraZeneca Paying Too Much for Alexion?

CRISPR Therapeutics

Here's how three nascent drugmakers could make 2021 a banner year for your portfolio.

3 Biotech Stocks That Could Explode Higher in 2021

NEW YORK, Dec. 18, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company") (ALXN)...

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Alexion Pharmaceuticals, Inc. - ALXN

NEW YORK, Dec. 16, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) concerning potential violations of the federal securities laws and/or breaches of fiduciary...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Companies - ALXN, CATM, TCP, PRVL

Here's why AstraZeneca's shareholders can expect healthy returns from this $39 billion investment.

3 Reasons AstraZeneca's Merger With Alexion Will Work for Investors

NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) breached their fiduciary duties or violated the federal securities laws in connection with the company's acquisition by AstraZeneca PLC (NASDAQ: AZN).

ALEXION ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of ALXN and Encourages Investors to Contact the Firm

Seeking Alpha Transcripts | Healthcare AstraZeneca PLC (AZN) AstraZeneca to acquire Alexion Conference Call (Transcript) Dec. 15, 2020 9:50 AM ET | | About: AstraZeneca PLC (AZN), AZNCF by: SA Transcripts Subscribers Only Earning Call Audio AstraZeneca PLC (NASDAQ:AZN) AstraZeneca to acquire Alexion Conference Call December 12, 2020 9:00 AM ET Company Participants Nick Stone - IR, AstraZeneca Pascal Soriot - CEO, AstraZeneca

News for Alexion Pharma Stock (ALXN)